NBCCGA: CENTRAL CYTOLOGY AND PATHOLOGY LABORATORY

NBCCGA：中央细胞学和病理学实验室

• 批准号: 3557922
• 负责人: RONALD S. WEINSTEIN
• 金额: $ 5万
• 依托单位: RUSH UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-07-01 至 1988-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3557922
• 关键词: biopsy; bladder neoplasm; cancer registry /resource; carcinoma; cooperative study; cystoscopy; diagnosis quality /standard; diagnosis service; exfoliative cytology; histopathology; human subject; human therapy evaluation; longitudinal human study; neoplasm /cancer classification /staging; neoplasm /cancer diagnosis; neoplasm /cancer immunodiagnosis; tumor antigens

The objective of the clinical research effort of National Bladder Cancer Collaborative Group A is to improve the care of patients with bladder carcinoma through studies of different aspects of clinical management according to carefully designed protocols. These are conducted at several Collaborating Institutions (CI) by multidisciplinary teams of physicians, including urologists, radiation therapists, medical oncologists and pathologists. A Central Statistical Office is responsible for collection organization and analyses of data, and an Administrative Center is responsible for program coordination and control. A Central Pathology Laboratory is responsible for the uniform evaluation, classification and analysis of pathologic and cytologic material. The Central Pathology Laboratory (CPL) proposes to: 1) Confirm the diagnosis of bladder cancer at the time of patient entry into the NBCCGA Surveillance Protocol (Ia) and to confirm the presence of those specific histopathologic features which will determine the eligibility of patients for specific therapy protocols; 2) to provide detailed histopathologic and cytologic information to the Statistical Center on review of accessioned material; 3) to review appropriate histologic material with CI pathologists looking particularly at cases with diagnostic differences between CPL and CI pathologists in order to expand our use of pathologic prognostic indicators; 4) to work with GI cytopathologists toward the acceptance and utilization of a standard method for evaluating and processing cytologic preparations; 5) to test the usefulness of cell surface markers as predictors of the aggressive potential of bladder carcinomas; 6) to provide resources, support and leadership within NBCCGA for the evaluation and interpretation of cytologic and histopathologic data.

国家膀胱癌临床研究工作的目标 协作组A是提高膀胱癌患者的护理水平 通过研究临床管理的不同方面来研究癌症 根据精心设计的协议。 这些活动在几个 多学科医生团队的合作机构（CI）， 包括泌尿科医生、放射治疗师、医学肿瘤学家和 病理学家 中央统计局负责收集 组织和分析数据，管理中心是 负责项目的协调和控制。 中心病理学 实验室负责统一评价、分类和 病理和细胞学材料分析。 中心病理学 实验室（CPL）建议：1）确认膀胱癌的诊断 在患者进入NBCCGA监测方案（Ia）时， 以确认存在那些特定的组织病理学特征， 将确定患者是否有资格接受特定治疗方案; 2)提供详细的组织病理学和细胞学信息， 统计中心对入库材料进行审核; 3）审核 适当的组织学材料，CI病理学家特别关注 CPL和CI病理学家之间存在诊断差异的病例， 为了扩大我们对病理预后指标的使用; 4）工作 与GI细胞病理学家对接受和利用一个 评价和处理细胞学制备物的标准方法; 5） 测试细胞表面标记物作为侵袭性 膀胱癌的潜力; 6）提供资源，支持和 NBCCGA内部的领导，用于评估和解释细胞学 和组织病理学数据。